Inventurus Knowledge Solutions IPO Listing Share Price Live Updates: Check listing date, time, GMP price, and other details

Go to Live Updates

Inventurus Share Price, GMP, Allotment Status Live: The company is all set to hit the D-Street on December 19. The allotment of shares was finalised on December 17. It was subscribed to a total of 52.68 times. The retailers booked the issue 14.55 times. The QIBs dominated the subscription with 80.64 times bidding. 

IKS raised Rs 2,497.92 crore by selling 1.88 crore shares of promoters and other selling shareholders. The IPO bidding was started on December 12 and ended on December 16. ICICI Securities, Jefferies India, JM Financial, J.P. Morgan India, and Nomura Financial Advisor and Securities (India) worked as the book-running lead managers of the IPO. Catch all the live updates on the listing of IKS IPO on our live blog.

Also Read Inventurus Knowledge Solutions IPO: This Rekha-Jhunjhunwala backed IPO opens tomorrow- Price band, GMP, and other key details Mobikwik IPO GMP, Subscription Status Highlights: Check allotment, listing, and other details Toss The Coin IPO Day 1: IPO subscription status, GMP, listing date and other key details Dhanlaxmi Crop Science IPO: Details of NSE SME IPO allotment status, GMP, listing date, 7 other key details Live UpdatesInventurus Share Price, IPO Listing 2024 Live Updates 08:40 (IST) 19 Dec 2024 Inventurus Share Price Live Updates: GMP update

The company was fetching a premium of 31.68% in the grey market. This indicates a listing at a price of around Rs 1750. The grey market is an unofficial place to trade shares ahead of listing. Market participants keep an eye on GMP to track listing gains.

 » Read More

Related Articles

8th Pay Commission: Central govt to merge pay scales for Level 1-6 employees? Here’s what the new proposal says

8th Pay Commission: The National Council of Joint Consultative Machinery (JCM) Staff Side has submitted its recommendations for the Terms of Reference (ToR) for the 8th Central Pay Commission (CPC), advocating significant changes in pay structure, allowances and benefits for government employees. Among the key points of ToR is the proposal for merger of certain

Bharti Airtel Q3 Results: Profit surges 505.24% to Rs 14,781.20 crore, ARPU at Rs 245

Bharti Airtel on Thursday posted a profit of Rs 14,781.20 crore during the third quarter of FY25, reporting a growth of 505.24 per cent in comparison to Rs 2442.20 crore during the corresponding quarter of FY24. The telecom major recorded Q3 revenue from operations at Rs 45,129.30 crore, up 19.08 per cent as against Rs

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

8th Pay Commission: Central govt to merge pay scales for Level 1-6 employees? Here’s what the new proposal says

8th Pay Commission: The National Council of Joint Consultative Machinery (JCM) Staff Side has submitted its recommendations for the Terms of Reference (ToR) for the 8th Central Pay Commission (CPC), advocating significant changes in pay structure, allowances and benefits for government employees. Among the key points of ToR is the proposal for merger of certain

Bharti Airtel Q3 Results: Profit surges 505.24% to Rs 14,781.20 crore, ARPU at Rs 245

Bharti Airtel on Thursday posted a profit of Rs 14,781.20 crore during the third quarter of FY25, reporting a growth of 505.24 per cent in comparison to Rs 2442.20 crore during the corresponding quarter of FY24. The telecom major recorded Q3 revenue from operations at Rs 45,129.30 crore, up 19.08 per cent as against Rs

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain